MX2021007508A - Derivados de oxopiridina sustituidos. - Google Patents
Derivados de oxopiridina sustituidos.Info
- Publication number
- MX2021007508A MX2021007508A MX2021007508A MX2021007508A MX2021007508A MX 2021007508 A MX2021007508 A MX 2021007508A MX 2021007508 A MX2021007508 A MX 2021007508A MX 2021007508 A MX2021007508 A MX 2021007508A MX 2021007508 A MX2021007508 A MX 2021007508A
- Authority
- MX
- Mexico
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- substituted
- derivatives
- thrombotic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención se refiere a derivados de oxopiridina sustituidos y a procesos para su preparación, y también a su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular trastornos vasculares, preferentemente trastornos trombóticos o tromboembólicos y/o complicaciones trombóticas o tromboembólicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018122825 | 2018-12-21 | ||
PCT/EP2019/085983 WO2020127504A1 (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007508A true MX2021007508A (es) | 2021-08-05 |
Family
ID=69143542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007508A MX2021007508A (es) | 2018-12-21 | 2019-12-18 | Derivados de oxopiridina sustituidos. |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP3898633A1 (es) |
JP (1) | JP2022514303A (es) |
KR (1) | KR20210106504A (es) |
CN (1) | CN113474348A (es) |
AR (1) | AR117435A1 (es) |
AU (1) | AU2019407909B2 (es) |
BR (1) | BR112021009435A2 (es) |
CA (1) | CA3124220A1 (es) |
CL (1) | CL2021001613A1 (es) |
CO (1) | CO2021007908A2 (es) |
CR (1) | CR20210342A (es) |
DO (1) | DOP2021000128A (es) |
EA (1) | EA202191764A1 (es) |
EC (1) | ECSP21043895A (es) |
IL (1) | IL283990A (es) |
JO (1) | JOP20210161A1 (es) |
MA (1) | MA54521A (es) |
MX (1) | MX2021007508A (es) |
PE (1) | PE20211790A1 (es) |
SG (1) | SG11202104384PA (es) |
TW (1) | TW202039510A (es) |
WO (1) | WO2020127504A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11542245B2 (en) * | 2018-03-15 | 2023-01-03 | Bayer Pharma Aktiengesellschaft | Preparative process |
CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
JP2024508971A (ja) | 2021-03-09 | 2024-02-28 | バイエル・アクチエンゲゼルシヤフト | (4s)-24-クロロ-4-エチル-73-フルオロ-35-メトキシ-32,5-ジオキソ-14-(トリフルオロメチル)-32h-6-アザ-3(4,1)-ピリジナ-1(1)-[1,2,3]トリアゾラ-2(1,2),7(1)-5 ジベンゼナヘプタファン-74-カルボキサミドの結晶形態 |
IL305235A (en) | 2021-03-09 | 2023-10-01 | Bayer Ag | Pharmaceutical dosage forms containing (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)- 32H -6-aza-3(1,4)-pyridine -1 (1)-[3,2,1]triazol-2-(2,1),7(1)-dibenzeneheptapane-74-carboxamide |
CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
CA2918814C (en) | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
CA2928867A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2016046156A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
ES2716417T3 (es) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
WO2016046164A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
ES2712886T3 (es) | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
ES2722425T3 (es) | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas |
EP3197896B1 (de) | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
EP3271332A1 (de) * | 2015-03-19 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose |
JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
WO2017037051A1 (de) | 2015-09-04 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
-
2019
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en unknown
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en active Active
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR117435A1 (es) | 2021-08-04 |
AU2019407909A1 (en) | 2021-05-27 |
SG11202104384PA (en) | 2021-05-28 |
WO2020127504A1 (en) | 2020-06-25 |
CL2021001613A1 (es) | 2021-12-03 |
TW202039510A (zh) | 2020-11-01 |
CA3124220A1 (en) | 2020-06-25 |
JOP20210161A1 (ar) | 2023-01-30 |
CO2021007908A2 (es) | 2021-07-19 |
JP2022514303A (ja) | 2022-02-10 |
ECSP21043895A (es) | 2021-07-30 |
CN113474348A (zh) | 2021-10-01 |
EP3898633A1 (en) | 2021-10-27 |
EA202191764A1 (ru) | 2021-10-22 |
AU2019407909B2 (en) | 2023-05-25 |
BR112021009435A2 (pt) | 2021-08-17 |
IL283990A (en) | 2021-07-29 |
CR20210342A (es) | 2021-08-09 |
KR20210106504A (ko) | 2021-08-30 |
DOP2021000128A (es) | 2021-09-30 |
MA54521A (fr) | 2022-03-30 |
PE20211790A1 (es) | 2021-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210161A1 (ar) | مشتقات أكسوبيريدين تحمل بدائل | |
PH12018500057A1 (en) | Substituted oxopyridine derivatives | |
PH12020551973A1 (en) | Substituted dihydropyrazolo pyrazine carboxamide derivatives | |
TN2015000434A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
PH12016502015A1 (en) | Anti-factor d antibody variants and uses thereof | |
PH12016500065A1 (en) | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof | |
WO2016046156A8 (de) | Substituierte oxopyridin-derivate | |
WO2018042438A3 (en) | Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
PH12021550872A1 (en) | Therapeutic compounds | |
MX2021002916A (es) | Pirfenidona enriquecida con deuterio y métodos para su uso. | |
TN2016000107A1 (en) | Substituted phenylalanine derivatives | |
MY150931A (en) | Substituted oxazolidinones and their use | |
JOP20170113B1 (ar) | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها | |
PH12019500535A1 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
MX2021004860A (es) | Piridazinas novedosas. | |
PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
MX2019012153A (es) | N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso. | |
TN2015000523A1 (en) | Substituted benzoxazoles | |
DOP2024000024A (es) | Derivados de s-alaninato sustituidos | |
AU2016224843A8 (en) | Compositions and combinations for the treatment of angiogenesis diseases and disorders | |
WO2016092377A3 (ru) | Композиция, содержащая глюкозамин, фруктобарат кальция и витамин d для лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов и позвоночника |